Please ensure Javascript is enabled for purposes of website accessibility

Elanco Announces Sale of Aqua Business to Merck Animal Health for $1.3B

By Pet Age Staff//February 5, 2024//

Elanco Announces Sale of Aqua Business to Merck Animal Health for $1.3B

By: Pet Age Staff//February 5, 2024//

Listen to this article

Press release: Elanco

Elanco Animal Health Incorporated recently announced it has entered into an agreement to sell its aqua business to Merck Animal Health for approximately $1.3 billion in cash, which represents approximately 7.4 times the estimated 2023 revenue of the Elanco aqua business.

“A strategic decision resulting from a disciplined process over the last year, the sale of the aqua business allows us to prioritize our investments in larger markets with greater earnings potential over the medium and long term, while creating balance sheet flexibility,” said Jeff Simmons, president and CEO of Elanco Animal Health. “We are focused on delivering consistent high impact innovation and continue to have confidence in our late-stage pipeline with six potential blockbuster products expected in the U.S. market by 2025. Further, we are advancing our next wave of development projects, which we believe will contribute meaningful growth for Elanco through the second half of the decade. Importantly, the proceeds from this transaction combined with improved free cash flow from the business, will accelerate deleveraging with net debt to adjusted EBITDA expected in the high-3x to low-4x range by the end of 2025.”

The transaction reinforces Elanco’s focus and investment on its most significant value creation opportunities, notably in pet health and livestock sustainability. In addition to the expected U.S. approvals in the first half of 2024 for Credelio Quattro, Zenrelia and Bovaer, Elanco is pursuing a portfolio of clinical development projects that the company expects to have differentiated profiles and blockbuster potential in significant markets with meaningful growth and earnings potential. Elanco’s targeted areas of focus include next generation products for pet parasiticides, dermatology and pain, as well as livestock sustainability. Additionally, the company is opportunistically pursuing platform-aligned targets, such as monoclonal antibodies, and other major emerging spaces of high unmet need.

“We are excited for the acquisition of Elanco’s aqua products, solutions as well as the capabilities and expertise the team brings to our business,” said Rick DeLuca, president, Merck Animal Health. “We believe this acquisition, coupled with our commercial and scientific prowess, will deliver enhanced benefits for our aqua customers. The addition of this innovative portfolio of cold water and warm water aqua products across vaccines, anti-parasitic treatments, water supplements and nutrition, will establish Merck Animal Health as a leader in aqua.”

Transaction Details
Elanco’s aqua business includes products across both warm-water and cold-water species, generating an estimated $175 million in revenue and approximately $92 million in adjusted EBITDA, excluding the allocation of corporate costs, based on 2023 preliminary results. The divestiture includes current marketed brands, aqua R&D projects, the transfer of manufacturing sites in Prince Edward Island, Canada and Dong Nai, Vietnam and approximately 280 commercial and manufacturing employees.

Upon closing of the transaction, Elanco plans to use the expected $1.05 billion to $1.1 billion of after-tax cash proceeds to pay down a portion of the Term Loan B debt. Elanco’s preliminary full year 2023 results, which do not include the effect of the sale of the aqua business, project net debt to adjusted EBITDA to be slightly below the midpoint of the company’s previous guidance range (5.5x to 5.8x). Giving pro forma effect to the transaction for the full year 2023, including the expected debt paydown and excluding the EBITDA associated with the aqua business, the company estimates the net leverage ratio would have been 0.6x to 0.7x lower, at or slightly below 5.0x. In 2024, with the anticipated debt paydown resulting from the transaction and from cash generated by the base business, the company expects to end the year with net debt to adjusted EBITDA in the mid-4x range. Further, the company expects net debt to adjusted EBITDA in high-3x to low-4x range by the end of 2025, driven by innovation fueled growth and continued debt paydown from improving free cash flow.

The expected retirement of a portion of the Term Loan B debt will result in reduced interest expense of approximately $65 million, or $0.11 of EPS, annually. For 2023, based on the midpoint of the company’s previous adjusted EPS guidance ($0.91), net EPS dilution would be approximately $0.03, or about 3 percent, while the company will be able to reduce net debt by approximately 20 percent.

The transaction, which is subject to regulatory approvals and customary closing conditions and adjustments, is expected to close around mid-year. The company plans to discuss the transaction further when it releases its fourth quarter and full year fiscal 2023 financial results on February 26, 2024.

BofA Securities, Inc. is serving as the company’s exclusive financial advisor and White & Case LLP is serving as the company’s legal advisor in connection with the transaction.